Details of the Drug Combination

General Information of Drug Combination (ID: DC8PZKM)

Drug Combination Name
Valproic Acid Guanfacine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Valproic Acid   DMS49KH Guanfacine   DMPN5IH
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 10.06
Bliss Independence Score: 10.06
Loewe Additivity Score: 24.36
LHighest Single Agent (HSA) Score: 24.36

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Valproic Acid
Disease Entry ICD 11 Status REF
Absence epilepsy N.A. Approved [2]
Epilepsy 8A60-8A68 Approved [2]
Glioblastoma 2A00 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Neuroblastoma 2D11.2 Investigative [2]
Indication(s) of Guanfacine
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [4]
Alzheimer disease 8A20 Phase 3 [5]
Guanfacine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Agonist [6]
------------------------------------------------------------------------------------
Guanfacine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Valproic Acid FDA Label
3 Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.
4 Guanfacine FDA Label
5 ClinicalTrials.gov (NCT03116126) Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease. U.S.National Institutes of Health.
6 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
7 An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat. 2011;7:501-5.